Jump Financial’s Royalty Pharma RPRX Stock Holding History

Jump Financial’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$933K	Sell	16,648 -34,022	-67%	-$1.77M	0.01%	1224
2026 Q1	$2.43M	Sell	50,670 -293,282	-85%	-$12.8M	0.03%	583
2025 Q4	$13.3M	Buy	343,952 +295,380	+608%	+$11.3M	0.16%	144
2025 Q3	$1.71M	Buy	+48,572	New	+$1.76M	0.02%	788
2025 Q2	–	Sell	-78,635	Closed	-$2.45M	–	2111
2025 Q1	$2.45M	Sell	78,635 -3,220	-4%	-$102K	0.03%	523
2024 Q4	$2.09M	Buy	+81,855	New	+$2.17M	0.04%	496
2024 Q1	–	Sell	-11,300	Closed	-$317K	–	2243
2023 Q4	$317K	Sell	11,300 -191,700	-94%	-$5.27M	0.01%	1302
2023 Q3	$5.51M	Sell	203,000 -253,285	-56%	-$7.52M	0.2%	94
2023 Q2	$14M	Buy	+456,285	New	+$15.5M	0.52%	15
2023 Q1	–	Sell	-8,651	Closed	-$342K	–	1988
2022 Q4	$342K	Buy	8,651 +1,436	+20%	+$59.9K	0.02%	966
2022 Q3	$290K	Buy	+7,215	New	+$308K	0.01%	1171
2022 Q1	–	Sell	-9,806	Closed	-$391K	–	1860
2021 Q4	$391K	Buy	+9,806	New	+$381K	0.02%	766

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jump Financial's RPRX Position: Q2 2026 in Review

Jump Financial reduced its Royalty Pharma (RPRX) stake by 67% in Q2 2026, selling an estimated $1.77M and leaving 16,648 shares worth $933K. The position accounts for 0.01% of the portfolio, ranked #1224.

Jump Financial first reported a position in RPRX in Q4 2021 and has held it in 12 quarters since. The position peaked at $14M in Q2 2023. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Jump Financial held 16,648 shares of Royalty Pharma worth $933K as of Q2 2026.
Jump Financial sold 34,022 Royalty Pharma shares in Q2 2026, an estimated $1.77M.
Royalty Pharma made up 0.01% of Jump Financial's portfolio in Q2 2026, its #1224 holding.
Jump Financial first reported a position in Royalty Pharma in Q4 2021 and has held it in 12 quarters since.
Jump Financial's Royalty Pharma position peaked at $14M in Q2 2023.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.